Rank #1824AVDL

Avadel Pharmaceuticals plc

$21.64

0.00% (Daily)

Market Cap

$2.12B

Revenue

$248.52M

Rank by MCap

#1824

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Headquarters

Dublin

Employees

188

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 201...